{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_180", "document_index": 23, "latency_s": 1.7886760999972466, "prompt_toks": 51656, "completion_toks": 86, "relevance_score": 0.0001465313}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    OLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nDecontamination. Administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Consider whole-bowel irrigation after ingestion of sustained-release products (eg, MS-Contin, OxyContin). /Opiates and opioids/\n\nOLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nEnhanced elimination. Because of the very large volumes of distribution of the opioids and the availability of an effective antidotal treatment, there is no role for enhanced elimination procedures. /Opiates and opioids/\n\nOLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nFor more Antidote and Emergency Treatment (Complete) data for CODEINE (8 total), please visit the HSDB record page.\n\n\n                    Context: \n                    This excerpt summarizes key emergency management guidelines for opioid overdose, specifically indicating that activated charcoal is appropriate for decontamination after small to moderate ingestions, and that there is no role for enhanced elimination due to opioids' large volume of distribution. It references the full section on antidote and emergency treatment for codeine available on the HSDB record, emphasizing its relevance within the comprehensive chemical safety and toxicity profile outlined in the overall webpage content.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_179", "document_index": 23, "latency_s": 1.757763799992972, "prompt_toks": 51462, "completion_toks": 100, "relevance_score": 2.2827997e-05}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    should be observed for at least 8-12 hours after the last dose of nalmefene. Sodium bicarbonate may be effective for QRS-interval prolongation or hypotension associated with propoxyphene poisoning. /Opiates and opioids/\n\n\n                    Context: \n                    This excerpt is from the section on antidote and emergency treatment of opiate and opioid poisoning, detailing post-treatment observation periods for drugs like nalmefene and related management of complications such as QRS prolongation or hypotension caused by toxins like propoxyphene. It emphasizes monitoring durations (8-12 hours) after nalmefene administration and mentions the potential use of sodium bicarbonate for specific cardiotoxic effects, highlighting critical first aid considerations within the comprehensive toxicity and treatment overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_155", "document_index": 23, "latency_s": 1.828357699996559, "prompt_toks": 51509, "completion_toks": 98, "relevance_score": 2.1444948e-05}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    were not prescribed an opioid, those born to mothers prescribed codeine were less likely to be admitted to hospital in the 30 days after the index date (hazard ratio 0.74). Admissions for and feeding difficulties were less common among infants of mothers who filled a codeine prescription than among infants of mothers who did not fill a codeine prescription. No infant deaths occurred. Of note is that the median drug supply was for 3 days (IQR 2-4).[14]\n\n\n                    Context: \n                    This excerpt summarizes a study on the effects of maternal codeine prescriptions during breastfeeding, highlighting reduced infant hospital admissions and feeding difficulties when mothers used the medication for a median of 3 days. It is relevant to the document’s discussion of codeine’s safety during lactation, infant exposure risks, and pharmacogenetic considerations, providing specific data on maternal prescribing patterns and infant health outcomes. This information enhances understanding of the clinical implications of maternal codeine use and informs risk assessment related to breastfeeding safety.\n                "}
